Matinas BioPharma (MTNB) To See Positive Benefits from Amarin (AMRN) News says Maxim
Tweet Send to a Friend
Maxim Group analyst Jason McCarthy maintains Buy on Matinas BioPharma Holdings Inc. (NYSE: MTNB) price target of $2.00.The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
